New drug combo tested to shrink tumors before esophageal cancer surgery
NCT ID NCT07430579
Summary
This study is testing a new treatment approach for people with a type of esophageal cancer that can be surgically removed. Before surgery, patients receive a combination of an immunotherapy drug (adebrelimab) and standard chemotherapy. The main goal is to see if this pre-surgery treatment can completely eliminate the cancer in the removed tissue and to check how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for QUALITY OF LIFE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Qilu Hospital of Shandong University
RECRUITINGJinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.